• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

博舒替尼引起胸腔积液:病例报告及酪氨酸激酶抑制剂所致肺毒性的综述

Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.

作者信息

Moguillansky Natalia I, Fakih Hafiz Abdul Moiz, Wingard John R

机构信息

University of Florida, Pulmonary, Critical Care and Sleep Medicine, P.O. Box 100225 JHMHC, Gainesville, FL 32610-0225, USA.

University of Florida, UF Health Bone Marrow Transplant - Shands Hospital, 1515 SW Archer Rd, Suite #100, Gainesville, FL 32608, USA.

出版信息

Respir Med Case Rep. 2017 May 10;21:154-157. doi: 10.1016/j.rmcr.2017.05.003. eCollection 2017.

DOI:10.1016/j.rmcr.2017.05.003
PMID:28560147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5435591/
Abstract

Tyrosine kinase inhibitors are known to cause pulmonary complications. We report a case of bosutinib related bilateral pleural effusions in a patient with chronic myeloid leukemia. Characteristics of the pleural fluid are presented. We also discuss other tyrosine kinase inhibitors induced pulmonary toxicities, including pulmonary hypertension and interstitial lung disease.

摘要

已知酪氨酸激酶抑制剂会引发肺部并发症。我们报告了一例慢性髓性白血病患者使用博舒替尼后出现双侧胸腔积液的病例。文中呈现了胸腔积液的特征。我们还讨论了其他酪氨酸激酶抑制剂诱发的肺部毒性,包括肺动脉高压和间质性肺疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01dc/5435591/e8748b339972/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01dc/5435591/7a6446521f0c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01dc/5435591/e8748b339972/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01dc/5435591/7a6446521f0c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01dc/5435591/e8748b339972/gr2.jpg

相似文献

1
Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.博舒替尼引起胸腔积液:病例报告及酪氨酸激酶抑制剂所致肺毒性的综述
Respir Med Case Rep. 2017 May 10;21:154-157. doi: 10.1016/j.rmcr.2017.05.003. eCollection 2017.
2
A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.一例在先前接受达沙替尼治疗后使用博舒替尼导致肺动脉高压和胸腔积液加重的病例。
Pulm Circ. 2017 Oct-Dec;7(4):808-812. doi: 10.1177/2045893217733444. Epub 2017 Oct 24.
3
Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.博舒替尼相关的间质性肺疾病和胸腔积液:一例报告及文献综述。
Clin Case Rep. 2021 May 7;9(5):e03164. doi: 10.1002/ccr3.3164. eCollection 2021 May.
4
Incident pulmonary arterial hypertension associated with Bosutinib.与博舒替尼相关的新发肺动脉高压
Pulm Circ. 2020 Aug 21;10(3):2045894020936913. doi: 10.1177/2045894020936913. eCollection 2020 Jul-Sep.
5
Dasatinib-Induced Bilateral Pleural Effusions.达沙替尼诱发双侧胸腔积液。
Cureus. 2022 Apr 7;14(4):e23906. doi: 10.7759/cureus.23906. eCollection 2022 Apr.
6
Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.慢性髓性白血病靶向治疗的心血管并发症
Curr Treat Options Cardiovasc Med. 2017 Apr;19(4):24. doi: 10.1007/s11936-017-0524-8.
7
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.达沙替尼治疗慢性粒细胞白血病后的肺部异常:病例系列
Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8. doi: 10.1164/rccm.200705-715CR. Epub 2007 Jun 28.
8
Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome.急性和慢性白血病及骨髓增生异常综合征中的胸腔积液
Curr Opin Pulm Med. 2014 Jul;20(4):340-6. doi: 10.1097/MCP.0000000000000060.
9
Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management.用于治疗慢性期慢性髓性白血病的酪氨酸激酶抑制剂:长期患者护理与管理
J Adv Pract Oncol. 2016 Jan-Feb;7(1):42-54. doi: 10.6004/jadpro.2016.7.1.3. Epub 2016 Jan 1.
10
Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension.胸腔积液与慢性肺动脉高压及右心房高压之间无关联。
Chest. 1987 Dec;92(6):967-70. doi: 10.1378/chest.92.6.967.

引用本文的文献

1
Bosutinib-Induced Pleural Effusion-Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors.博舒替尼引起的胸腔积液——类效应及对所有酪氨酸激酶抑制剂的交叉不耐受
Hematol Rep. 2025 Jan 31;17(1):7. doi: 10.3390/hematolrep17010007.
2
Bosutinib-induced lung injury: a report of two cases and literature review.博舒替尼致肺损伤:两例报告及文献复习。
Int J Hematol. 2022 Jun;115(6):902-905. doi: 10.1007/s12185-022-03304-0. Epub 2022 Feb 28.
3
Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

本文引用的文献

1
Discontinuation of TKI therapy and 'functional' cure for CML.酪氨酸激酶抑制剂(TKI)治疗的中断与慢性粒细胞白血病(CML)的“功能性”治愈
Best Pract Res Clin Haematol. 2016 Sep;29(3):308-313. doi: 10.1016/j.beha.2016.10.014. Epub 2016 Oct 20.
2
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.ABL酪氨酸激酶抑制剂停止用于慢性髓性白血病研究的当前状况。
Stem Cell Investig. 2016 Aug 9;3:36. doi: 10.21037/sci.2016.07.08. eCollection 2016.
3
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.
博舒替尼相关的间质性肺疾病和胸腔积液:一例报告及文献综述。
Clin Case Rep. 2021 May 7;9(5):e03164. doi: 10.1002/ccr3.3164. eCollection 2021 May.
酪氨酸激酶抑制剂所致间质性肺疾病:临床特征、诊断挑战及治疗困境
Drug Saf. 2016 Nov;39(11):1073-1091. doi: 10.1007/s40264-016-0450-9.
4
Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.慢性粒细胞白血病中酪氨酸激酶抑制剂治疗的停药:当前认识与未来方向
Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):488-494. doi: 10.1016/j.clml.2016.06.012. Epub 2016 Jun 16.
5
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.DASISION的5年最终研究结果:达沙替尼与伊马替尼治疗初治慢性髓性白血病患者的试验
J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.
6
The concept of treatment-free remission in chronic myeloid leukemia.慢性髓性白血病中无治疗缓解的概念。
Leukemia. 2016 Aug;30(8):1638-47. doi: 10.1038/leu.2016.115. Epub 2016 May 2.
7
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.酪氨酸激酶抑制剂在慢性髓性白血病中的长期副作用
Curr Hematol Malig Rep. 2016 Apr;11(2):71-9. doi: 10.1007/s11899-016-0309-2.
8
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.接受达沙替尼治疗的肺动脉高压患者的临床特征。
Am J Hematol. 2015 Nov;90(11):1060-4. doi: 10.1002/ajh.24174. Epub 2015 Oct 12.
9
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.博舒替尼用于对伊马替尼和其他酪氨酸激酶抑制剂耐药/不耐受的晚期白血病患者的长期疗效和安全性。
Am J Hematol. 2015 Sep;90(9):755-68. doi: 10.1002/ajh.24034. Epub 2015 Jun 1.
10
Tyrosine kinase inhibitor induced isolated pericardial effusion.
Case Rep Oncol. 2015 Feb 13;8(1):88-93. doi: 10.1159/000375484. eCollection 2015 Jan-Apr.